Skip to content

Insmed INSM Free cash flow

Free cash flow at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$204.76M+67.3%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
-$47.4M-48.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$52.3M+60.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Savara logo
SavaraSVRA
-$33.1M-21.7%
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%

Valuation

See full
Market cap$23.11B+25.2%
Enterprise value$23.11B+29.9%
P/S28.2×-18.2×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp
FCF margin-112.5%-35.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Calculated from Insmed’s reported figures.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's free cash flow?
Insmed (INSM) reported free cash flow of -$226.22M in Q1 2026.
How has Insmed's free cash flow changed year-over-year?
Insmed's free cash flow increased by 16.9% year-over-year, from -$272.16M to -$226.22M.
What is the long-term trend for Insmed's free cash flow?
Over 4 years (2021 to 2025), Insmed's free cash flow has grown at a 27.1% compound annual growth rate (CAGR), from -$370.59M to -$967.58M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.